T1	Participants 400 479	Patients with extensive SCLC with a Karnofsky performance score (KPS) > or = 50
T2	Participants 547 589	Patients with CNS metastases were eligible
T3	Participants 1079 1181	All patients were assessable for survival; 163 were fully assessable for response and 162 for toxicity
T4	Participants 946 1008	From May 1989 through March 1993, 171 patients were randomized
T5	Participants 1304 1380	patients treated with VP and VIP, respectively (difference not significant).
T6	Participants 1768 1832	overall survival over VP therapy in patients with extensive SCLC
